Cure Rtd Foundation

Organization Overview

Cure Rtd Foundation is located in Red Oak, TX. The organization was established in 2018. According to its NTEE Classification (G12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Voluntary Health Associations & Medical Disciplines and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Cure Rtd Foundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.

For the year ending 12/2023, Cure Rtd Foundation generated $380.5k in total revenue. This organization has experienced exceptional growth, as over the past 5 years, it has increased revenue by an average of 11.2% each year . All expenses for the organization totaled $258.1k during the year ending 12/2023. While expenses have increased by 20.8% per year over the past 5 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.

Mission & Program ActivityExcerpts From the 990 Filing

TAX YEAR

2023

Describe the Organization's Mission:

Part 3 - Line 1

TO ENCOURAGE, GUIDE, AND FUND ADDITIONAL RESEARCH TO IMPROVE UNDERSTANDING, DIAGNOSIS, AND TREATMENT OF RIBOFLAVIN TRANSPORTER DEFICIENCY ("RTD").

Describe the Organization's Program Activity:

Part 3 - Line 4a

CURE RTD FOUNDATION IS PROUD TO HAVE FUNDED THE FOUR FOLLOWING RESEARCH PROJECTS IN ADVANCEMENT OF THE UNDERSTANDING AND TREATMENT OF RTD: (A) $120,000 INTO A 2-YEAR PROJECT AIMED TO GAIN FURTHER INSIGHTS INTO THE STRUCTURE/FUNCTION RELATIONSHIPS ENSURING THE CORRECT FUNCTIONING OF RFVT2, WHOSE PERTURBATIONS ARE AT THE BASES OF A SEVERE NEURODEGENERATIVE DISORDER, NAMELY RTD TYPE 2 (OMIM # 614707); (B) $18,685 TO INVESTIGATE THE ROLE OF THE BLOOD BRAIN BARRIER IN RIBOFLAVIN TRANSPORT IN PATIENTS WITH RTD; (C) $51,990 INTO A 2-YEAR PROJECT TO BEGIN UNDERSTANDING THE EYE DEFECTS OF RTD PATIENTS BY DEVELOPING IPSC-DERIVED RETINAL ORGANOIDS: A 3D MODEL TO TEST THE EFFICACY OF THE AAV GENE THERAPY; AND (D) $34,596 TO COVER COSTS TO SET UP, OPTIMIZE, AND RUN FLAVIN TESTING ON 222 MOUSE BRAIN AND BLOOD SAMPLES.


Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Board, Officers & Key Employees

Name (title)Compensation
Carly Gilbert
VP / Treasurer
$15,000
Clayton Greene
Secretary
$0
Keith Massey
Director
$0
Chad Griffith
President
$0

Financial Statements

Statement of Revenue
Federated campaigns$70
Membership dues$0
Fundraising events$0
Related organizations$0
Government grants $0
All other contributions, gifts, grants, and similar amounts not included above$380,178
Noncash contributions included in lines 1a–1f $0
Total Revenue from Contributions, Gifts, Grants & Similar$380,248
Total Program Service Revenue$0
Investment income $0
Tax Exempt Bond Proceeds $0
Royalties $291
Net Rental Income $0
Net Gain/Loss on Asset Sales $0
Net Income from Fundraising Events $0
Net Income from Gaming Activities $0
Net Income from Sales of Inventory $0
Miscellaneous Revenue$0
Total Revenue $380,539

Create an account to unlock the data you need.

or